ARC-sparX : A Modular & Universal Cell Platform

Time: 11:45 am
day: Day 2 - Track B - Morning


  • An overview of the ARC-sparX platform and how it may be used to address some of the limitations of standard CAR-T cells therapies
  • Modular approach allows for multiple tumour antigen targeting with a universal cell product
  • Control of effector cell and antigen interaction has potential to control expansion kinetics and therefore toxicity profile
  • Combined, this approach may reduce exhaustion, improve efficacy against heterogeneous tumours, and minimise toxicity related to uncontrolled cell expansion